Brenda Fernanda Moreira Castro

Dr. Brenda Fernanda Moreira Castro

orcid

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
25 October 2023 in BioDrugs
Verified
Journal Article
Open access
PDF file
BCBrenda Fernanda Moreira Castro
Brenda Fernanda Moreira Castro
JSJason Steel
Jason Steel
CLChristopher J. Layton
Christopher J. Layton
Age-related macular degeneration (AMD) and diabetic retinopathy (DR) are vascular diseases with high prevalence, ranking among the leading causes of blindness and vision loss worldwide. Despite being effective, current treatments for AMD and DR are burdensome for patients and clinicians, resulting in suboptimal compliance and real risk of vision loss. Thus, there is an unmet need for long-lasting alternatives with improved safety and efficacy. Adeno-associated virus (AAV) is the leading vector for ocular gene delivery, given its ability to enable long-term expression while eliciting relatively mild immune responses. Progress has been made in AAV-based gene therapies for not only inherited retinal diseases but also acquired conditions with preclinical and clinical studies of AMD and DR showing promising results. These studies have explored several pathways involved in the disease pathogenesis, as well as different strategies to optimise gene delivery. These include engineered capsids with enhanced tropism to particular cell types, and expression cassettes incorporating elements for a targeted and controlled expression. Multiple-acting constructs have also been investigated, in addition to gene silencing and editing. Here, we provide an overview of strategies employing AAV-mediated gene delivery to treat AMD and DR. We discuss preclinical efficacy studies and present the latest data from clinical trials for both diseases. Graphical Abstract

15 April 2024 in Expert Reviews in Molecular Medicine
Verified
Journal Article
Open access
PDF file
BCBrenda Fernanda Moreira Castro
Brenda Fernanda Moreira Castro
JSJason Steel
Jason Steel
CLChristopher J. Layton
Christopher J. Layton
Glaucoma and uveitis are non-vascular ocular diseases which are among the leading causes of blindness and visual loss. These conditions have distinct characteristics and mechanisms but share a multifactorial and complex nature, making their management challenging and burdensome for patients and clinicians. Furthermore, the lack of symptoms in the early stages of glaucoma and the diverse aetiology of uveitis hinder timely and accurate diagnoses, which are a cause of poor visual outcomes under both conditions. Although current treatment is effective in most cases, it is often associated with low patient adherence and adverse events, which directly impact the overall therapeutic success. Therefore, long-lasting alternatives with improved safety and efficacy are needed. Gene therapy, particularly utilising adeno-associated virus (AAV) vectors, has emerged as a promising approach to address unmet needs in these diseases. Engineered capsids with enhanced tropism and lower immunogenicity have been proposed, along with constructs designed for targeted and controlled expression. Additionally, several pathways implicated in the pathogenesis of these conditions have been targeted with single or multigene expression cassettes, gene editing and silencing approaches. This review discusses strategies employed in AAV-based gene therapies for glaucoma and non-infectious uveitis and provides an overview of current progress and future directions.

1 April 2020 in International Immunopharmacology
Verified
Journal Article
Closed access
BCBrenda Fernanda Moreira Castro
Brenda Fernanda Moreira Castro
LVLorena Carla Vieira
Lorena Carla Vieira
DVDaniel Vitor Vasconcelos-Santos
Daniel Vitor Vasconcelos-Santos
SCSarah Pereira de Freitas Cenachi
Sarah Pereira de Freitas Cenachi
OCOliver Araújo Lacerda Cotta
Oliver Araújo Lacerda Cotta
SFSílvia Ligório Fialho
Sílvia Ligório Fialho

1 October 2016 in Journal of Drug Delivery Science and Technology
Verified
Journal Article
Closed access
GSGisele R. Silva
Gisele R. Silva
AAAna Paula R. Almeida
Ana Paula R. Almeida
GFGabriella M. Fernandes-Cunha
Gabriella M. Fernandes-Cunha
BCBrenda Fernanda Moreira Castro
Brenda Fernanda Moreira Castro
LVLorena C. Vieira
Lorena C. Vieira
SFSílvia Ligório Fialho
Sílvia Ligório Fialho

11 May 2022 in Current Research in Pharmacology and Drug Discovery
Verified
Journal Article
Open access
BCBrenda Fernanda Moreira Castro
Brenda Fernanda Moreira Castro
CSCarolina Silva
Carolina Silva
LCLídia Pereira Barbosa Cordeiro
Lídia Pereira Barbosa Cordeiro
SCSarah Pereira de Freitas Cenachi
Sarah Pereira de Freitas Cenachi
DVDaniel Vitor Vasconcelos-Santos
Daniel Vitor Vasconcelos-Santos
SFSílvia Ligório Fialho
Sílvia Ligório Fialho
Uveitis is a group of sight-threatening ocular inflammatory disorders, whose mainstay of therapy is associated with severe adverse events, prompting the investigation of alternative treatments. The peptide melittin (MEL) is the major component of Apis mellifera bee venom and presents anti-inflammatory and antiangiogenic activities, with possible application in ophthalmology. This work aims to investigate the potential of intravitreal MEL in the treatment of ocular diseases involving inflammatory processes, especially uveitis. Safety of MEL was assessed in retinal cells, chick embryo chorioallantoic membranes, and rats. MEL at concentrations safe for intravitreal administration showed an antiangiogenic activity in the chorioallantoic membrane model comparable to bevacizumab, used as positive control. A protective anti-inflammatory effect in retinal cells stimulated with lipopolysaccharide (LPS) was also observed, without toxic effects. Finally, rats with bacille Calmette-Guerin- (BCG) induced uveitis treated with intravitreal MEL showed attenuated disease progression and improvement of clinical, morphological, and functional parameters, in addition to decreased levels of proinflammatory mediators in the posterior segment of the eye. These effects were comparable to the response observed with corticosteroid treatment. Therefore, MEL presents adequate safety profile for intraocular administration and has therapeutic potential as an anti-inflammatory and antiangiogenic agent for ocular diseases.

1 March 2017 in Journal Français d'Ophtalmologie
Verified
Journal Article
Closed access
AFA.E.R. Ferreira
A.E.R. Ferreira
BCBrenda Fernanda Moreira Castro
Brenda Fernanda Moreira Castro
LVL.C. Vieira
L.C. Vieira
GCG.D. Cassali
G.D. Cassali
CSC.M. Souza
C.M. Souza
SFSílvia Ligório Fialho
Sílvia Ligório Fialho